$BIXT
BIOXYTRAN, INC Stock $bixt

$bixt Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224042763 Filed on October 29, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$482.3K
YoY Change			-15.88%
% of Gross Profit
Research & Development		$51.00K	$544.4K
YoY Change		-83.87%	149.02%
% of Gross Profit
Depreciation & Amortization			$3.780K
YoY Change			315.38%
% of Gross Profit
Operating Expenses		$346.2K	$1.031M
YoY Change		-64.87%	29.97%
Operating Profit		-$346.2K
YoY Change		-64.87%
Interest Expense			-$37.79K
YoY Change			-40.78%
% of Operating Profit
Other Income/Expense, Net		-$46.17K
YoY Change		-8.58%
Pretax Income		-$392.4K	-$1.068M
YoY Change		-62.12%	24.7%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		-$392.4K	-$1.047M
YoY Change		-60.81%	29.89%
Net Earnings / Revenue
Basic Earnings Per Share		$0.00
Diluted Earnings Per Share		$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	85.78M shares	178.0M shares	144.6M shares
Diluted Shares Outstanding		126.4M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$26.09K
YoY Change		-91.17%
Cash & Equivalents	$34.67K	$26.09K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$34.67K	$26.09K
YoY Change	-56.81%	-91.17%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$124.3K	$111.6K
YoY Change	14.31%	47.68%
TOTAL ASSETS
Total Short-Term Assets	$34.67K	$26.09K
Total Long-Term Assets	$124.3K	$111.6K
Total Assets	$159.0K	$137.6K
YoY Change	-15.89%	-62.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$298.3K
YoY Change		-57.97%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt		$1.900M
YoY Change		-12.24%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.244M	$3.250M
YoY Change	-46.7%	-11.3%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.244M	$3.250M
Total Long-Term Liabilities		$0.00
Total Liabilities	$1.244M	$3.250M
YoY Change	-46.7%	-11.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.30M	-$15.50M
YoY Change	26.63%	38.15%
Common Stock	$17.19M	$145.6K
YoY Change	11804.95%	18.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$2.431M
YoY Change
Total Liabilities & Shareholders Equity	$159.0K	$137.6K
YoY Change	-15.89%	-62.89%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	-$392.4K	-$1.047M
YoY Change	-60.81%	29.89%
Depreciation, Depletion And Amortization		$3.780K
YoY Change		315.38%
Cash From Operating Activities		-$92.63K
YoY Change		-40.88%
INVESTING ACTIVITIES
Capital Expenditures		$6.560K
YoY Change		212.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$6.560K
YoY Change		212.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		45.00K
YoY Change		-43.75%
NET CHANGE
Cash From Operating Activities		-92.63K
Cash From Investing Activities		-6.560K
Cash From Financing Activities		45.00K
Net Change In Cash		-54.19K
YoY Change		-31.22%
FREE CASH FLOW
Cash From Operating Activities		-$92.63K
Capital Expenditures		$6.560K
Free Cash Flow		-$99.19K
YoY Change		-37.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 605
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001445815
CY2023Q4	us-gaap	Assets Current AssetsCurrent	26086	usd
	dei	Document Type DocumentType	10-Q
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	BIXT
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	85782908	shares
CY2024Q3	us-gaap	Cash Cash	34672	usd
CY2023Q4	us-gaap	Cash Cash	26086	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	34672	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2024Q3	us-gaap	Minority Interest MinorityInterest		usd
CY2023Q3	BIXT	Interest Expense Affiliate InterestExpenseAffiliate		usd
	BIXT	Interest Expense Affiliate InterestExpenseAffiliate		usd
CY2024Q3	BIXT	Loss On Issuance LossOnIssuance		usd
	BIXT	Loss On Issuance LossOnIssuance		usd
CY2023Q3	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2024Q1	BIXT	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised		usd
CY2024Q3	BIXT	Stock Issued During Period Value Conversion To Pref Stock Affiliate StockIssuedDuringPeriodValueConversionToPrefStockAffiliate		usd
CY2024Q3	BIXT	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised		usd
CY2024Q3	BIXT	Stock Issued During Period Elimination Non Contr Int StockIssuedDuringPeriodEliminationNonContrInt		usd
	BIXT	Loss On Issuance LossOnIssuance		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants		usd
	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	BIXT	Common Shares Issued For Conversion Of Accounts Payable CommonSharesIssuedForConversionOfAccountsPayable		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities		usd
CY2024Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent		usd
CY2023Q4	BIXT	Debt Discount DebtDiscount		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity File Number EntityFileNumber	001-35027
	dei	Entity Registrant Name EntityRegistrantName	BIOXYTRAN, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2797630
	dei	Entity Address Address Line1 EntityAddressAddressLine1	75 2nd Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Needham Heights
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02494-2863
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	454-1199
CY2024Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	124336	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	111552	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	124336	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	111552	usd
CY2024Q3	us-gaap	Assets Assets	159008	usd
CY2023Q4	us-gaap	Assets Assets	137638	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	98426	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	72553	usd
CY2024Q3	BIXT	Convertible Notes Payable Net Of Premium And Discount Current ConvertibleNotesPayableNetOfPremiumAndDiscountCurrent	755000	usd
CY2023Q4	BIXT	Convertible Notes Payable Net Of Premium And Discount Current ConvertibleNotesPayableNetOfPremiumAndDiscountCurrent	1900000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1243578	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3249500	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1243578	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3249500	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	28893618	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	28893618	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	28894	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145642333	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	82239	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	145642	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17103158	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	13012670	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-680886	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1084570	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159008	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137638	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	316129	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	604771	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	153886	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	768050	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3249500	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	28893618	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	28893618	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	28894	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82238648	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82238648	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145642333	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145642333	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	82239	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	145642	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17103158	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	13012670	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-680886	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18298861	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15589288	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1084570	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159008	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137638	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	316129	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	604771	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	153886	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	232778	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	768050	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	893217	usd
CY2024Q3	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	102447	usd
CY2023Q3	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	298000	usd
	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	488523	usd
	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	1138130	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	8416	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	81318	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	187517	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	82528	usd
CY2024Q3	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	30455	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	217290	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	74740	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	346204	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	985465	usd
	us-gaap	Operating Expenses OperatingExpenses	1739380	usd
	us-gaap	Operating Expenses OperatingExpenses	2793386	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-346204	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-985465	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1739380	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	893217	usd
CY2023Q3	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	298000	usd
	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	488523	usd
	BIXT	General And Administrative Affiliate GeneralAndAdministrativeAffiliate	1138130	usd
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	8416	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	81318	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	187517	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	82528	usd
CY2024Q3	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	30455	usd
CY2023Q3	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	57240	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	217290	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	74740	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	346204	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	985465	usd
	us-gaap	Operating Expenses OperatingExpenses	1739380	usd
	us-gaap	Operating Expenses OperatingExpenses	2793386	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-346204	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-985465	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1739380	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2793386	usd
CY2024Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	17845	usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	48701	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	63950	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	155399	usd
CY2024Q3	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	1809	usd
	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	4324	usd
CY2023Q3	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1516	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1803	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4505	usd
CY2024Q3	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	25000	usd
	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	55000	usd
	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	348637	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46170	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142190	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-600227	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-392374	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1127655	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1867737	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-392374	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1127655	usd
	us-gaap	Profit Loss ProfitLoss	-1867737	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34777	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-68435	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-392374	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1092878	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1854413	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3325178	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2793386	usd
CY2024Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	17845	usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	48701	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	63950	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	155399	usd
CY2024Q3	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	1809	usd
	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	4324	usd
CY2023Q3	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1516	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4505	usd
CY2024Q3	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	25000	usd
	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	55000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46170	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142190	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-128357	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-600227	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-392374	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1127655	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1867737	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3393613	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-392374	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1127655	usd
	us-gaap	Profit Loss ProfitLoss	-1867737	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34777	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-68435	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-392374	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1092878	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1854413	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3325178	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	126391176	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	136443056	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153821016	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153821016	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129441332	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129441332	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3292546	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-30000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32894	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-785083	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4060523	usd
CY2024Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	17845	usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	48701	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	63950	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	155399	usd
CY2024Q3	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	1809	usd
	BIXT	Interest Expense Affiliate InterestExpenseAffiliate	4324	usd
CY2023Q3	BIXT	Loss On Issuance LossOnIssuance	91686	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1516	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4505	usd
CY2024Q3	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	25000	usd
	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	55000	usd
	BIXT	Debt Discount Amortization And Issuance Of Warrants DebtDiscountAmortizationAndIssuanceOfWarrants	348637	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46170	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-142190	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-128357	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-600227	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-392374	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1127655	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1867737	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3393613	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-392374	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-1127655	usd
	us-gaap	Profit Loss ProfitLoss	-1867737	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34777	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-392374	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1092878	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1854413	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3325178	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126391176	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	126391176	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	136443056	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153821016	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129441332	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3292546	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-30000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32894	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-785083	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	50200	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	1790	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	2164340	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	44050	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	172306	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	604771	usd
CY2024Q3	BIXT	Discount To Market Price Rate DiscountToMarketPriceRate	0.25	pure
CY2024Q3	us-gaap	Cash Cash	34672	usd
CY2024Q3	BIXT	Working Capital WorkingCapital	-1207907	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18298861	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	63000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	61500	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126391176	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	126391176	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	136443056	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	136443056	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	153821016	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	153821016	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129441332	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129441332	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3292546	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	80000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-30000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32894	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4060523	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	65000	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	50200	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	1790	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	2164340	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	44050	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	172306	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	348637	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-764	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1447218	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2662182	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	390361	usd
CY2023Q3	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	17940	usd
CY2023Q3	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	71312	usd
CY2023Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	830026	usd
CY2023Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	192000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	144282	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34777	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1092878	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2024Q1	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	131836	usd
CY2024Q1	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	168448	usd
CY2024Q1	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	485904	usd
CY2024Q1	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	885404	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1263562	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-800329	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	63000	usd
CY2024Q2	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	30000	usd
CY2024Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	10695	usd
CY2024Q2	BIXT	Stock Issued During Period Value Conversion Of Debt StockIssuedDuringPeriodValueConversionOfDebt	286125	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-661710	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1099956	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	65000	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	50200	usd
CY2023Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	1790	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	2164340	usd
CY2023Q2	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	44050	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	348637	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2662182	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	390361	usd
CY2023Q3	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	17940	usd
CY2023Q3	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	71312	usd
CY2023Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	830026	usd
CY2023Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	192000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	144282	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34777	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1092878	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2143916	usd
CY2024Q1	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	131836	usd
CY2024Q1	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	168448	usd
CY2024Q1	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	485904	usd
CY2024Q1	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	885404	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1263562	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-800329	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-990361	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	63000	usd
CY2024Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	10695	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-661710	usd
CY2024Q3	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	45455	usd
CY2024Q3	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	8465	usd
CY2024Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	353840	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-392374	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1084570	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1084570	usd
	us-gaap	Profit Loss ProfitLoss	-1867737	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	55000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	348637	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4505	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	187517	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	82528	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	217290	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	74740	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	164357	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	51588	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	565789	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	574654	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	2265953	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98047	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-682749	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17867	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37740	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	63000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	348637	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1447218	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2662182	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	390361	usd
CY2023Q3	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	17940	usd
CY2023Q3	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	71312	usd
CY2023Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	830026	usd
CY2023Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	192000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	144282	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-34777	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1092878	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2143916	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2024Q1	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	131836	usd
CY2024Q1	BIXT	Stock Issued During Period Value Conversion Of Debt Other StockIssuedDuringPeriodValueConversionOfDebtOther	885404	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1263562	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-13324	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-800329	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-990361	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	63000	usd
CY2024Q2	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	30000	usd
CY2024Q2	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	10695	usd
CY2024Q2	BIXT	Stock Issued During Period Value Conversion Of Debt StockIssuedDuringPeriodValueConversionOfDebt	286125	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	162295	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-661710	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1099956	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1099956	usd
CY2024Q3	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	45455	usd
CY2024Q3	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	8465	usd
CY2024Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	353840	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-392374	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1084570	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1084570	usd
	us-gaap	Profit Loss ProfitLoss	-1867737	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	55000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	348637	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4505	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	187517	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	82528	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	217290	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	74740	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	164357	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	51588	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	565789	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-208773	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	574654	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	2265953	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98047	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-682749	usd
CY2024Q3	BIXT	Stock Issued During Period Value Issuance Stock Plan Affiliate StockIssuedDuringPeriodValueIssuanceStockPlanAffiliate	45455	usd
CY2024Q3	BIXT	Stock Issued During Period Value Issuance Issuance Stock Plan Other StockIssuedDuringPeriodValueIssuanceIssuanceStockPlanOther	8465	usd
CY2024Q3	BIXT	Stock Issued During Period Value Conversion Of Debt Affiliate StockIssuedDuringPeriodValueConversionOfDebtAffiliate	353840	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-392374	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1084570	usd
	us-gaap	Profit Loss ProfitLoss	-1867737	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	55000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	348637	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5083	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4505	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	187517	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	82528	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	217290	usd
	BIXT	Stockbased Compensation Expense Affiliate StockbasedCompensationExpenseAffiliate	74740	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	164357	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	51588	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	565789	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-208773	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	574654	usd
	BIXT	Increase Decrease In Accounts Payable Affiliate IncreaseDecreaseInAccountsPayableAffiliate	2265953	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98047	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-682749	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17867	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	37740	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17867	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	63000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	505361	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	61500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	505361	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8586	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-215128	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26086	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	295401	usd
	us-gaap	Interest Paid Net InterestPaidNet	52425	usd
	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants	348637	usd
	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote	55000	usd
	BIXT	Common Shares Issued For Conversion Of Notes Payable And Accrued Interest CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest	1425857	usd
	BIXT	Common Shares Issued For Conversion Of Notes Payable And Accrued Interest CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest	316588	usd
	us-gaap	Stock Issued1 StockIssued1	1171529	usd
	BIXT	Common Shares Issued For Conversion Of Accounts Payable CommonSharesIssuedForConversionOfAccountsPayable	839744	usd
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82238648	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	28893618	shares
CY2023Q3	us-gaap	Liabilities Liabilities	2332959	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	144355	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12913571	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-659063	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14542779	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189043	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17867	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	37740	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17867	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37740	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	63000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	505361	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	61500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	505361	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8586	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26086	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	295401	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34672	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	80273	usd
	us-gaap	Interest Paid Net InterestPaidNet	52425	usd
	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants	348637	usd
	BIXT	Debt Discount On Convertible Note DebtDiscountOnConvertibleNote	55000	usd
	BIXT	Common Shares Issued For Conversion Of Notes Payable And Accrued Interest CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest	1425857	usd
	BIXT	Common Shares Issued For Conversion Of Notes Payable And Accrued Interest CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest	316588	usd
	us-gaap	Stock Issued1 StockIssued1	1171529	usd
	BIXT	Common Shares Issued For Conversion Of Accounts Payable CommonSharesIssuedForConversionOfAccountsPayable	839744	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82238648	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82238648	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	28893618	shares
CY2023Q3	us-gaap	Assets Assets	189043	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2332959	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	144355	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12913571	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-659063	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14542779	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2143916	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189043	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2793386	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-600227	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-68435	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3325178	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129441332	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129441332	shares
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	91686	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-682749	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37740	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	505361	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-215128	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	505361	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	61500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	124500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8586	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-215128	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26086	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	295401	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	80273	usd
	us-gaap	Interest Paid Net InterestPaidNet	52425	usd
	BIXT	Non Cash Issuance Of Warrants NonCashIssuanceOfWarrants	348637	usd
	BIXT	Common Shares Issued For Conversion Of Notes Payable And Accrued Interest CommonSharesIssuedForConversionOfNotesPayableAndAccruedInterest	316588	usd
	us-gaap	Stock Issued1 StockIssued1	1171529	usd
	BIXT	Common Shares Issued For Conversion Of Accounts Payable CommonSharesIssuedForConversionOfAccountsPayable	839744	usd
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82238648	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	28893618	shares
CY2023Q3	us-gaap	Assets Assets	189043	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2332959	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	144355	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12913571	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	-659063	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14542779	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2143916	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189043	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2793386	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-600227	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-68435	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3325178	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129441332	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129441332	shares
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	91686	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	505361	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-215128	usd
CY2023Q4	us-gaap	Assets Assets	137638	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3249500	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	145642	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	13012670	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137638	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2793386	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-600227	usd
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-68435	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	129441332	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129441332	shares
	us-gaap	Profit Loss ProfitLoss	-3393613	usd
	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	91686	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-682749	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37740	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	505361	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-215128	usd
CY2023Q4	us-gaap	Assets Assets	137638	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3249500	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	145642	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	13012670	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-680886	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15589288	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137638	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zPYYIKQCwZ81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zlcg8DsVYiXe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Assets Assets	137638	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3249500	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	13012670	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15589288	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3111862	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	137638	usd
	BIXT	Loss On Issuance LossOnIssuance	91686	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zPYYIKQCwZ81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zlcg8DsVYiXe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zPYYIKQCwZ81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zlcg8DsVYiXe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, valuation of warrants, valuations in connection with convertible notes and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	604771	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	604771	usd
CY2024Q3	BIXT	Discount To Market Price Rate DiscountToMarketPriceRate	0.25	pure
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	604771	usd
CY2024Q3	BIXT	Discount To Market Price Rate DiscountToMarketPriceRate	0.25	pure
CY2024Q3	us-gaap	Cash Cash	34672	usd
CY2024Q3	BIXT	Working Capital WorkingCapital	-1207907	usd
CY2024Q3	BIXT	Discount To Market Price Rate DiscountToMarketPriceRate	0.25	pure
CY2024Q3	us-gaap	Cash Cash	34672	usd
CY2024Q3	BIXT	Working Capital WorkingCapital	-1207907	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	63000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	61500	usd
CY2024Q3	us-gaap	Cash Cash	34672	usd
CY2024Q3	BIXT	Working Capital WorkingCapital	-1207907	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	63000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	61500	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P2041Y
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	141348	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17012	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11928	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111552	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18298861	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	63000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	505361	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P2041Y
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	141348	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	123480	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	17012	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11928	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	124336	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111552	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	75469	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70895	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4332	usd
CY2024Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	18625	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1658	usd
CY2024Q3	BIXT	Debt Discount DebtDiscount	-50000	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	805000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P2041Y
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	141348	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	124336	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111552	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	75469	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70895	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4332	usd
CY2024Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	18625	usd
CY2024Q3	BIXT	Debt Discount DebtDiscount	-50000	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	805000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1900000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1243578	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3249500	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1900000	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	223759	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2123759	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	Each share of Preferred Stock has the voting power of ten (10) shares of Common Stock, and can at any time be converted into five (5), shares of Common Stock. The number of shares of Preferred Stock issued and outstanding during the reporting period(s)
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.20
CY2024Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P2041Y
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	141348	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11928	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111552	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	75469	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70895	usd
CY2024Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	18625	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1658	usd
CY2024Q3	BIXT	Debt Discount DebtDiscount	-50000	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	805000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1900000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1243578	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3249500	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1900000	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	223759	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2123759	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	Each share of Preferred Stock has the voting power of ten (10) shares of Common Stock, and can at any time be converted into five (5), shares of Common Stock. The number of shares of Preferred Stock issued and outstanding during the reporting period(s)
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.20
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	542030	shares
CY2022Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.42
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	800000	shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.20
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted	P5Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q3	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
CY2024Q3	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	75469	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	70895	usd
CY2024Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4332	usd
CY2024Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	18625	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1658	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	805000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1900000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3249500	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	223759	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2123759	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	Each share of Preferred Stock has the voting power of ten (10) shares of Common Stock, and can at any time be converted into five (5), shares of Common Stock. The number of shares of Preferred Stock issued and outstanding during the reporting period(s)
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	800000	shares
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.20
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	542030	shares
CY2022Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.42
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	800000	shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.20
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted	P5Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q3	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
CY2023	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2024Q3	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1900000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3249500	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1900000	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	223759	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2123759	usd
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	Each share of Preferred Stock has the voting power of ten (10) shares of Common Stock, and can at any time be converted into five (5), shares of Common Stock. The number of shares of Preferred Stock issued and outstanding during the reporting period(s)
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.20
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	542030	shares
CY2022Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.42
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	800000	shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.20
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted	P5Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q3	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	26712247	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	542030	shares
CY2022Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.42
CY2022	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	800000	shares
	BIXT	Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	0.20
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermGranted	P5Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1342030	shares
CY2023Q3	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2023Q4	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
CY2023	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2024Q3	BIXT	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.29
	BIXT	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P3Y
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	26712247	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8973405	shares
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	26712247	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8973405	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	26712247	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8973405	shares
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8973405	shares

Files In Submission

Name	View Source	Status
0001493152-24-042763-index-headers.html	Edgar Link	pending
0001493152-24-042763-index.html	Edgar Link	pending
0001493152-24-042763.txt	Edgar Link	pending
0001493152-24-042763-xbrl.zip	Edgar Link	pending
bixt-20240930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
bixt-20240930_def.xml	Edgar Link	unprocessable
bixt-20240930_cal.xml	Edgar Link	unprocessable
bixt-20240930_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bixt-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
0001493152-24-042763-index-headers.html	Edgar Link	pending
0001493152-24-042763-index.html	Edgar Link	pending
0001493152-24-042763.txt	Edgar Link	pending
0001493152-24-042763-xbrl.zip	Edgar Link	pending
bixt-20240930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
bixt-20240930_cal.xml	Edgar Link	unprocessable
bixt-20240930_def.xml	Edgar Link	unprocessable
bixt-20240930_lab.xml	Edgar Link	unprocessable
bixt-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIXT
BIOXYTRAN, INC Stock $bixt

2024 Q4 Form 10-Q Financial Statement

#000149315224042763 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT BIOXYTRAN, INC Stock $bixt

2024 Q4 Form 10-Q Financial Statement

#000149315224042763 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIXT
BIOXYTRAN, INC Stock $bixt